17 completed, 3 terminated, 2 withdrawn. 14 Phase 3, 7 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 14 | Completed 11, Terminated 2, Withdrawn 1 |
| Phase 2 | 7 | Completed 5, Terminated 1, Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
Follow gaboxadol: new trials by email Literature Review of gaboxadol trials Research Report on gaboxadol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Placebo-Controlled, Single-Dose Challenge Study of Gaboxadol in Adult Males With Fragile X Syndrome (FXS) Gaboxadol, Placebo - Fragile X Syndrome | Phase 2 | Completed | Craig Erickson | 10 | 2024-01-29 | 2026-09-30 |
| Investigation of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) in Male Fragile X Syndrome Patients Aged 13-40 Sulindac (HLX-0201), dose strength 1, Sulindac (HLX-0201), dose strength 2, Placebo - Fragile X Syndrome | Phase 2 | Withdrawn | Healx Limited | 2022-05-25 | 2022-12-08 | |
| A Study of OV101 in Individuals With Angelman Syndrome (AS) Gaboxadol, Placebo - Primary Disease or Condition Being Studied: Angelman Syndrome (AS) | Phase 3 | Completed | Ovid Therapeutics Inc. | 104 | 2019-09-09 | 2024-01-08 |
| An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome OV101 - Angelman Syndrome | Phase 3 | Terminated | Healx AI | 141 | 2019-01-31 | 2025-07-18 |
| A Study of OV101 in Individuals With Fragile X Syndrome OV101 (gaboxadol) - Fragile X Syndrome (FXS) | Phase 2 | Completed | Ovid Therapeutics Inc. | 36 | 2018-09-17 | 2024-01-23 |
| Single Dose Pharmacokinetic (PK) Study OV101 - Angelman Syndrome, Fragile X Syndrome | Phase 1 | Completed | Ovid Therapeutics Inc. | 12 | 2017-04-03 | 2017-11-30 |
| A Study in Adults and Adolescents With Angelman Syndrome (STARS) OV101 Regimen 1, OV101 regimen 2, Placebo - Angelman Syndrome | Phase 2 | Completed | Healx AI | 88 | 2016-01-01 | 2025-08-03 |
| Short-term Study of Combination Treatment of Escitalopram and Gaboxadol in Major Depressive Disorder Escitalopram placebo, Gaboxadol placebo, Escitalopram 20 mg - Major Depressive Disorder | Phase 2 | Completed | H. Lundbeck A/S | 490 | 2008-11-01 | 2012-12-17 |
| MK0928 Study in Adult Patients With Primary Insomnia (0928-040)(COMPLETED) MK0928, gaboxadol / Duration of Treatment 3 Weeks, Placebo / Duration of Treatment 3 Weeks - Primary Insomnia | Phase 2 | Completed | H. Lundbeck A/S | 520 | 2005-11-01 | 2015-01-14 |
| Sleep Laboratory Study of MK0928 in Adult Patients With Primary Insomnia (0928-041)(TERMINATED) MK0928, gaboxadol / Duration of Treatment: 6 days for treatment periods (2 days/dose), Placebo / Duration of Treatment: 2 days for screening period - Primary Insomnia | Phase 2 | Terminated | H. Lundbeck A/S | 50 | 2005-11-01 | 2015-01-14 |
| An Investigational Study of MK0928 in Adult Outpatients With Insomnia (0928-014)(COMPLETED) gaboxadol, Comparator: placebo (unspecified) - Insomnia | Phase 3 | Completed | H. Lundbeck A/S | 900 | 2005-02-01 | 2015-01-14 |
| Study of MK0928 in Healthy Adult Volunteers in a Model of Insomnia (0928-006)(COMPLETED) gaboxadol - Insomnia | Phase 3 | Completed | H. Lundbeck A/S | 663 | 2005-02-01 | 2015-01-14 |
| An Investigational Drug Study in Healthy Adult Volunteers in a Model of Insomnia (0928-007) MK0928, gaboxadol / Duration of Treatment: 10 months - Insomnia | Phase 3 | Withdrawn | H. Lundbeck A/S | 2005-01-01 | 2015-01-14 | |
| Elderly Primary Insomnia Polysomnographic Study (0928-002)(TERMINATED) MK0928, gaboxadol / Duration of Treatment - 6 weeks, Comparator: placebo / Duration of Treatment - 6 weeks - Primary Insomnia | Phase 3 | Terminated | H. Lundbeck A/S | 465 | 2004-11-01 | 2015-01-14 |
| Adult Primary Insomnia Polysomnographic Study (0928-004)(COMPLETED) gaboxadol, Comparator: placebo (unspecified) - Primary Insomnia | Phase 3 | Completed | H. Lundbeck A/S | 465 | 2004-11-01 | 2015-01-14 |
| Efficacy and Safety of MK0928 for Insomnia in Adults (0928-003)(COMPLETED) MK0928, gaboxadol / Duration of Treatment - 1 year, Comparator: placebo / Duration of Treatment -1 year - Insomnia | Phase 3 | Completed | H. Lundbeck A/S | 600 | 2004-10-01 | 2015-01-14 |
| Safety of MK0928 on Insomnia in the Elderly (0928-005)(COMPLETED) MK0928, gaboxadol, Comparator: placebo - Insomnia | Phase 3 | Completed | H. Lundbeck A/S | 320 | 2004-10-01 | 2016-11-17 |
| A Prospective Open-Label Extension Study of Gaboxadol in Primary Insomnia Gaboxadol - Primary Insomnia | Phase 3 | Completed | H. Lundbeck A/S | 200 | 2004-07-01 | 2007-03-30 |
| A Study of Gaboxadol in Primary Insomnia Gaboxadol - Primary Insomnia | Phase 3 | Completed | H. Lundbeck A/S | 320 | 2004-06-01 | 2007-03-30 |
| A Study of Gaboxadol in Primary Insomnia Gaboxadol - Primary Insomnia | Phase 3 | Completed | H. Lundbeck A/S | 505 | 2004-04-01 | 2007-03-30 |
Showing 20 of 22. Sign in to see all of them.
Sleep Initiation and Maintenance Disorders (14) · Fragile X Syndrome (4) · Angelman Syndrome (3) · Depressive Disorder, Major (1)
H. Lundbeck A/S (15) · Ovid Therapeutics Inc. (3) · Healx AI (2) · Craig Erickson (1) · Healx Limited (1)
United States (7) · Israel (3) · Australia (2) · Germany (2) · Sweden (2) · Austria (1) · Netherlands (1) · Russia (1)
Amit Rakhit, MD (1) · Amit Rakhit, MD, MBA (1) · Cragi A Erickson, MD (1) · Elizabeth Berry-Kravis (1)
PMID 20191935, PMID 31926466, PMID 22003345, PMID 22008735, PMID 33395098, PMID 33443117, PMID 34690787, PMID 37639777, PMID 42104256
2008 (1)